The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Targeted therapy based on germline analysis of tumor-normal sequencing (MSK-IMPACT) in a pan-cancer population.
 
Zsofia Kinga Stadler
Consulting or Advisory Role - Adverum (I); Alimera Sciences (I); Allergan (I); Biomarin (I); Fortress Biotech (I); Genentech/Roche (I); Novartis (I); Optos (I); Regeneron (I); Regenxbio (I); Spark Therapeutics (I)
 
Anna Maio
No Relationships to Disclose
 
Yelena Kemel
No Relationships to Disclose
 
Margaret Sheehan
No Relationships to Disclose
 
Erin E. Salo-Mullen
No Relationships to Disclose
 
Karen Anne Cadoo
Honoraria - OncLive
Consulting or Advisory Role - GlaxoSmithKline/Tesaro
Research Funding - AstraZeneca (Inst); Syndax (Inst)
Travel, Accommodations, Expenses - AstraZeneca
 
Maria Isabel Carlo
Consulting or Advisory Role - Pfizer
Other Relationship - Prostate Cancer Foundation; Robert Wood Johnson Foundation
 
Alicia Latham
Other Relationship - Conquer Cancer Foundation
 
Michael Francis Walsh
No Relationships to Disclose
 
Alexander E. Drilon
Honoraria - Foundation Medicine; Medscape; MORE Health; OncLive; Peerview; PeerVoice; Physicans' Education Resource; Research to Practice; Targeted Oncology
Consulting or Advisory Role - AstraZeneca; Bayer; BeiGene; BerGenBio; Blueprint Medicines; Exelixis; Genentech/Roche; Helsinn Therapeutics; Hengrui Therapeutics; Ignyta; Lilly; Loxo; MORE Health; Pfizer; Takeda/Millennium; TP Therapeutics; Tyra Biosciences; Verastem; Verastem
Research Funding - Foundation Medicine
Patents, Royalties, Other Intellectual Property - Wolters Kluwer (Royalties for Pocket Oncology)
Other Relationship - GlaxoSmithKline; Merck; Pfizer; PharmaMar; Puma Biotechnology; Taiho Pharmaceutical; Teva
 
Michael F. Berger
Consulting or Advisory Role - Roche
Research Funding - Grail
 
David B. Solit
Stock and Other Ownership Interests - Loxo
Consulting or Advisory Role - Illumina; Intezyne Technologies; Lilly; Loxo; Pfizer; QED Therapeutics; Vividion Therapeutics
Travel, Accommodations, Expenses - Merck KGaA
 
Ozge Birsoy
No Relationships to Disclose
 
Diana Mandelker
No Relationships to Disclose
 
Luis A. Diaz
Leadership - Jounce Therapeutics; Personal Genome Diagnostics
Stock and Other Ownership Interests - Amgen (I); Jounce Therapeutics; Neophore; PapGene, Inc.; Personal Genome Diagnostics; Thrive Earlier Detection Corp; Zydecom
Consulting or Advisory Role - Caris Life Sciences; Cell Design Labs; Genocea Biosciences; Lyndra Therapeutics; Merck; Neophore; Personal Genome Diagnostics; Zydecom
Research Funding - Merck (Inst)
Patents, Royalties, Other Intellectual Property - EP-2912468-B1 - Papanicolaou test for ovarian and endometrial cancers; EP-3322824-A1 - Detection of tumor-derived dna in cerebrospinal fluid; US-2005202465-A1 - Thymidylate synthase gene and metastasis; US-2010041048-A1 - Circulating Mutant DNA to Assess Tumor Dynamics; US-2013323167-A1 - Detecting and treating solid tumors through selective disruption of tumor vasculature; US-2014227271-A1 - Somatic mutations in atrx in brain cancer; US-2015252415-A1 - Arid1b and neuroblastoma; US-2015344970-A1 - Personalized Tumor Biomarkers; US-2016208340-A1 - TERT Promoter Mutations in Urothelial Neoplasia; US-2016273049-A1 - Systems and methods for analyzing nucleic acid (Inst); US-2017016075-A1 - Neoantigen analysis (Inst); US-2017267760-A1 - Checkpoint Blockade and Microsatellite Instability; US-2018086832-A1 - Hla-restricted epitopes encoded by somatically mutated genes; US-2018135044-A1 - Non-unique barcodes in a genotyping assay (Inst); US-2018171413-A1 - Head and neck squamous cell carcinoma assays; US-2018171413-A1 - Head and neck squamous cell carcinoma assays; US-2018171413-A1 - Head and neck squamous cell carcinoma assays; US-2018258490-A1 - Assaying ovarian cyst fluid; US-9976184-B2 - Mutations in pancreatic neoplasms; WO-2010118016-A2 - Digital quantification of dna methylation; WO-2012094401-A2 - Genes frequently altered in pancreatic neuroendocrine tumors; WO-2018071796-A2 - Compositions and methods for identifying functional anti-tumor t cell responses
Travel, Accommodations, Expenses - Merck
 
Kenneth Offit
No Relationships to Disclose
 
Mark E. Robson
Honoraria - AstraZeneca
Consulting or Advisory Role - Change HealthCare
Research Funding - Abbvie (Inst); AstraZeneca (Inst); InVitae (Inst); Medivation (Inst); Myriad Genetics (Inst); Pfizer (Inst); Tesaro (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Pfizer
Other Relationship - Clinical Care Options; Physicans' Education Resource; Research to Practice
(OPTIONAL) Uncompensated Relationships - Daiichi Sankyo; Merck; Pfizer